Common AEs were nausea (23%), vomiting (6%), diarrhea (6%), constipation (10%), headache (6%), fatigue (8%), abdominal pain (2%), and abdominal bloating (2%)
Navigating Health and Wellness: Insights on GLP-1 Medications, Thyroid Health, and Hormone Therapy In a recent podcast episode, McCall McPherson delves into a variety of health topics, focusing on GLP-1 medications, thyroid health, and hormone therapy
Unlike semaglutide, which focuses primarily on GLP-1 receptor activation to manage blood sugar and appetite, Personalized GLP-1targets additional metabolic pathways for a more comprehensive weight management solution
The main agents currently approved by the EMA and/or FDA include exenatide (2005/2005), liraglutide (2009/2010), lixisenatide (2013/2016), dulaglutide (2014/2014), semaglutide (2017/2017
But, like any treatment, peptide therapy isnt one-size-fits-all